WESTMINSTER, Colo. — Westminster-based biotech company Arca Biopharma has submitted an Investigational New Drug application for COVID-19.
The application was filed under the Coronavirus Treatment Acceleration Program. The application will evaluate the use of one of Arca Biopharma's drugs, AB201, as a treatment for patients hospitalized with COVID-19.
The 13-employee Arca Biopharma typically focuses on genetically targeted therapies for cardiovascular diseases. AB201 is believed to be effective with RNA viruses, which includes COVID-19 but also SARS and Ebola. At the end of August, Arca Biopharma told Denver Business Journal that this Investigational New Drug application would be a critical step in development.
“We have a compound with a mechanism that could work directly against a disease that comes in the form of a virus and we’re in a pandemic,” Derek Cole, head of investor relations for the company, said at the time. “We have the opportunity to help with that response. We’ve seen how quickly the biopharma industry has responded in a collaborative way to move things along quickly and to help with the tragic situation we’re all in. We take it as a responsibility to move forward and see if our drug does help.”
> Top stories curated daily just for you! Sign up for the 9NEWSLETTER to get can’t-miss stories, Next and Broncos content, weather and more delivered right to your inbox.
SUGGESTED VIDEOS: COVID-19 Coronavirus
MORE WAYS TO GET 9NEWS
Subscribe to our daily 9NEWSLETTER
HOW TO ADD THE 9NEWS APP TO YOUR STREAMING DEVICE
ROKU: add the channel from the ROKU store or by searching for KUSA.
For both Apple TV and Fire TV, search for "9news" to find the free app to add to your account. Another option for Fire TV is to have the app delivered directly to your Fire TV through Amazon.